Editorial for “Relationship Between Simulated Gadolinium‐Based Contrast Agent Injection Profile and Achievable Resolution Metrics in Contrast‐Enhanced Magnetic Resonance Angiography”

2021 ◽  
Author(s):  
Giles Roditi
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Angiography ◽  
Contrast Agent ◽  
Contrast Enhanced ◽  
Contrast Agent Injection

scholarly journals Contrast-Enhanced Magnetic Resonance Angiography Using a Novel Elastin-Specific Molecular Probe in an Experimental Animal Model

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Carolin Reimann ◽  
Julia Brangsch ◽  
Jan Ole Kaufmann ◽  
Lisa C. Adams ◽  
David C. Onthank ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Image Quality ◽  
Magnetic Resonance Angiography ◽  
Contrast Agent ◽  
Mr Angiography ◽  
Molecular Probe ◽  
Time Resolved ◽  
Clinical Dose ◽  
Contrast Enhanced ◽  
First Pass

Objectives. The aim of this study was to test the potential of a new elastin-specific molecular agent for the performance of contrast-enhanced first-pass and 3D magnetic resonance angiography (MRA), compared to a clinically used extravascular contrast agent (gadobutrol) and based on clinical MR sequences. Materials and Methods. Eight C57BL/6J mice (BL6, male, aged 10 weeks) underwent a contrast-enhanced first-pass and 3D MR angiography (MRA) of the aorta and its main branches. All examinations were on a clinical 3 Tesla MR system (Siemens Healthcare, Erlangen, Germany). The clinical dose of 0.1 mmol/kg was administered in both probes. First, a time-resolved MRA (TWIST) was acquired during the first-pass to assess the arrival and washout of the contrast agent bolus. Subsequently, a high-resolution 3D MRA sequence (3D T1 FLASH) was acquired. Signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) were calculated for all sequences. Results. The elastin-specific MR probe and the extravascular imaging agent (gadobutrol) enable high-quality MR angiograms in all animals. During the first-pass, the probes demonstrated a comparable peak enhancement (300.6 ± 32.9 vs. 288.5 ± 33.1, p>0.05). Following the bolus phase, both agents showed a comparable intravascular enhancement (SNR: 106.7 ± 11 vs. 102.3 ± 5.3; CNR 64.5 ± 7.4 vs. 61.1 ± 7.2, p>0.05). Both agents resulted in a high image quality with no statistical difference (p>0.05). Conclusion. The novel elastin-specific molecular probe enables the performance of first-pass and late 3D MR angiography with an intravascular contrast enhancement and image quality comparable to a clinically used extravascular contrast agent.

Angiography for Diagnosing Peripheral Arterial Occlusive Disease – A Technical, Clinical and Cost Comparison of Contrast-enhanced Magnetic Resonance Angiography and Unenhanced Magnetic Resonance Imaging Techniques with a Focus on Fresh Blood Imaging

2010 ◽  
Vol 6 (2) ◽  
pp. 54
Author(s):  
Carsten Schwenke ◽  
Monica Boos ◽  
Rainer Hentrich ◽  
Michael Blankenburg ◽  
Martin Rohrer ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Angiography ◽  
Contrast Agent ◽  
Peripheral Arterial Occlusive Disease ◽  
Arterial Occlusive Disease ◽  
Occlusive Disease ◽  
Fresh Blood ◽  
Contrast Enhanced ◽  
Peripheral Arterial ◽  
Blood Imaging

This study compares the clinical and technical utility of non-contrast-enhanced magnetic resonance angiography (nce-MRA) and contrastenhanced MRA (ce-MRA) in a mini-review of patients with suspected peripheral arterial occlusive disease (PAOD) in whom both MRA approaches were indicated. It also looks at the costs of angiography for diagnosing peripheral arterial occlusive disease using either ce-MRA or nce-MRA in comparison with the example of fresh blood imaging (FBI). The costs for MRA were taken from a previous cost study and those for nce-MRA/FBI from published data and appropriate calculations. The average total investigation costs for ce-MRA were found to be €205, including €59 for consumables, mainly originating from the contrast agent costs (according to German list prices for 2009). On the other hand, for nce-MRA, average total costs ranged from €190 to €239, depending on the acquisition time (12–32 minutes), and a larger number of additional diagnostic investigations were found. Irrespective of costs, several clinical and technical benefits such as image quality, higher robustness and the absence of limitations with complex vessel courses favoured ce-MRA. The consequences of using ce-MRA were fewer technical failures and, therefore, a higher throughput of patients indicated for contrast agent use in the radiology department; this led to more procedures per day and, therefore, more efficient use of diagnostic imaging resources.

Sign in / Sign up

Export Citation Format

Share Document